Clinical-Scale TCR-T Cell Manufacturing Data with Cytokine Cocktail Protocol

Supplementary file 1 from a study by Yi-Ping Shih, last updated May 2026, details a 10-day protocol for manufacturing TCR-engineered T cells. The dataset likely contains phenotypic and functional metrics comparing cells produced with a novel cytokine cocktail (IL-2/7/15 and TGF-β) against a standard IL-2 protocol. It includes results from clinical-scale runs yielding up to 6.15 x 10^9 total cells.

Use Cases

• Compare T cell differentiation markers (e.g., CCR7, CD103, CD49a) between cytokine conditions.
• Analyze effector function correlations based on metrics like 4-1BB upregulation, IFN-γ, TNF, and granzyme B production.
• Evaluate in vitro tumor-killing efficacy using data from 2D and 3D spheroid co-culture assays.
• Assess scalability of manufacturing protocols using cell yield data from clinical-scale engineering runs.

Strengths

• Protocol details a specific 10-day manufacturing process with a defined cytokine cocktail.
• Includes comparative data from clinical-scale runs yielding 3.30 and 6.15 x 10^9 total cells.
• Evaluates multiple functional readouts: phenotype, cytokine production, and tumor cell killing.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is contained within a 487.8 KB PDF, which may require extraction for computational analysis.

Provenance

Source

Yi-Ping Shih via figshare

Collection Method

Patient-derived PBMC were stimulated, CD8+ enriched, retrovirally transduced, and expanded in cytokine conditions.

Freshness

Last updated 2026-05-15 04:22:59; freshness should be verified.